RELAPSING MULTIPLE SCLEROSIS

This study looked at the long-term safety and effectiveness of the drug SAR442168 in 125 people with relapsing multiple sclerosis who had already completed a previous study. Participants continued taking the drug for up to 240 weeks. The main goal was to track side effects, and t…

This study tested the drug ofatumumab in 99 Chinese adults with relapsing multiple sclerosis (RMS). The goal was to see if monthly injections could reduce the number of relapses and how safe the treatment was over one year. Participants received 20 mg of ofatumumab under the skin…

This study tested a new drug called SAR442168 in 130 adults with relapsing multiple sclerosis (MS). The goal was to see if different doses could reduce new active brain lesions seen on MRI scans. The drug works by blocking a protein involved in immune system attacks on the brain.…

This study looked at 111 adults with relapsing multiple sclerosis who switched from an IV anti-CD20 medication to a self-injected drug called ofatumumab. The goal was to see if the new treatment could keep their disease under control. After 12 months, most participants had no new…

This study looked at how well ofatumumab works in 562 people with relapsing multiple sclerosis who switched from other MS drugs (fumarates or fingolimod) because their disease was still active. The main goal was to see how many relapses occurred per year. Researchers also tracked…

This study followed 10 people with relapsing multiple sclerosis for 9 months to see how the drug ofatumumab affects microglia, the brain's immune cells. Researchers used special PET scans and blood tests to track changes. The goal was to understand how the drug works in the brain…

This study followed 103 adults with relapsing multiple sclerosis who were taking Kesimpta (ofatumumab). Researchers used a mobile app to track how often patients took their medication on time and compared their reported symptoms with clinical results. The goal was to better under…